These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 24619951)

  • 1. Liquid chromatography-tandem mass spectrometric assay for the multikinase inhibitor regorafenib in plasma.
    Luethi D; Durmus S; Schinkel AH; Schellens JH; Beijnen JH; Sparidans RW
    Biomed Chromatogr; 2014 Oct; 28(10):1366-70. PubMed ID: 24619951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liquid chromatography-tandem mass spectrometric assay for the ALK inhibitor crizotinib in mouse plasma.
    Sparidans RW; Tang SC; Nguyen LN; Schinkel AH; Schellens JH; Beijnen JH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Sep; 905():150-4. PubMed ID: 22940474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liquid chromatography-tandem mass spectrometric assay for the JAK2 inhibitor CYT387 in plasma.
    Sparidans RW; Durmus S; Xu N; Schinkel AH; Schellens JH; Beijnen JH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 May; 895-896():174-7. PubMed ID: 22476054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liquid chromatography-tandem mass spectrometric assay for the VEGFR inhibitor cediranib and its primary human metabolite cediranib-N⁺-glucuronide in plasma.
    Sparidans RW; Durmus S; Xu N; Schinkel AH; Schellens JH; Beijnen JH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 May; 895-896():169-73. PubMed ID: 22476055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liquid chromatography-tandem mass spectrometric assay for the PARP-1 inhibitor olaparib in combination with the nitrogen mustard melphalan in human plasma.
    Sparidans RW; Martens I; Valkenburg-van Iersel LB; den Hartigh J; Schellens JH; Beijnen JH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Jul; 879(21):1851-6. PubMed ID: 21622034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the tyrosine kinase inhibitor pazopanib in human plasma.
    Sparidans RW; Ahmed TT; Muilwijk EW; Welzen ME; Schellens JH; Beijnen JH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Sep; 905():137-40. PubMed ID: 22917595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor vemurafenib in human and mouse plasma.
    Sparidans RW; Durmus S; Schinkel AH; Schellens JH; Beijnen JH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Mar; 889-890():144-7. PubMed ID: 22386128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of the effect of plasma albumin levels on regorafenib-induced hepatotoxicity using a validated liquid chromatography-tandem mass spectrometry method.
    Pang YY; Tan YL; Ho HK
    J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Sep; 1061-1062():220-224. PubMed ID: 28750235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor dabrafenib in mouse plasma.
    Sparidans RW; Durmus S; Schinkel AH; Schellens JH; Beijnen JH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Apr; 925():124-8. PubMed ID: 23537694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liquid chromatography-tandem mass spectrometry assay for the EGFR inhibitor pelitinib in plasma.
    Luethi D; Durmus S; Schinkel AH; Schellens JH; Beijnen JH; Sparidans RW
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Sep; 934():22-5. PubMed ID: 23892825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma.
    Sparidans RW; Iusuf D; Schinkel AH; Schellens JH; Beijnen JH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Dec; 877(32):4090-6. PubMed ID: 19910267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An LC-MS/MS method for the quantitation of cabozantinib in rat plasma: application to a pharmacokinetic study.
    Su Q; Li J; Ji X; Li J; Zhou T; Lu W; Li L
    J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Mar; 985():119-23. PubMed ID: 25678398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liquid chromatography-tandem mass spectrometry assay for therapeutic drug monitoring of the tyrosine kinase inhibitor, midostaurin, in plasma from patients with advanced systemic mastocytosis.
    Bourget P; Amin A; Chandesris MO; Vidal F; Merlette C; Hirsch I; Cabaret L; Carvalhosa A; Mogenet A; Frenzel L; Damaj G; Lortholary O; Hermine O
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jan; 944():175-81. PubMed ID: 24316764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liquid chromatography-tandem mass spectrometric assay for the quantitative determination of the tyrosine kinase inhibitor quizartinib in mouse plasma using salting-out liquid-liquid extraction.
    Retmana IA; Wang J; Schinkel AH; Schellens JHM; Beijnen JH; Sparidans RW
    J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Sep; 1061-1062():300-305. PubMed ID: 28772226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liquid chromatography-tandem mass spectrometric assay for pravastatin and two isomeric metabolites in mouse plasma and tissue homogenates.
    Sparidans RW; Iusuf D; Schinkel AH; Schellens JH; Beijnen JH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Oct; 878(28):2751-9. PubMed ID: 20829130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liquid chromatography-tandem mass spectrometric assay for the cyclin-dependent kinase inhibitor AT7519 in mouse plasma.
    Dolman ME; den Hartog IJ; Molenaar JJ; Schellens JH; Beijnen JH; Sparidans RW
    J Pharm Biomed Anal; 2014 Jan; 88():216-20. PubMed ID: 24080524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly sensitive method for the determination of a novel triple kinase inhibitor with anti-cancer activity, JI-101, in rat plasma by liquid chromatography-electrospray ionization tandem mass spectrometry: application to a pharmacokinetic study.
    Gurav SD; Gilibili RR; Jeniffer S; Giri S; Srinivas NR; Mullangi R
    Biomed Chromatogr; 2011 Jul; 25(7):794-800. PubMed ID: 20872957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liquid chromatography-tandem mass spectrometric assay for the nucleoside reverse transcriptase inhibitor emtricitabine in human plasma.
    Sparidans RW; Prins JM; Schellens JH; Beijnen JH
    Biomed Chromatogr; 2007 Jun; 21(6):621-7. PubMed ID: 17340566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liquid chromatography-tandem mass spectrometric assay for sorafenib and sorafenib-glucuronide in mouse plasma and liver homogenate and identification of the glucuronide metabolite.
    Sparidans RW; Vlaming ML; Lagas JS; Schinkel AH; Schellens JH; Beijnen JH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jan; 877(3):269-76. PubMed ID: 19117812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liquid chromatography-tandem mass spectrometric assay for the PARP inhibitor rucaparib in plasma.
    Sparidans RW; Durmus S; Schinkel AH; Schellens JH; Beijnen JH
    J Pharm Biomed Anal; 2014 Jan; 88():626-9. PubMed ID: 24216281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.